Unassociated Document


    EXHIBIT
10.6

     

     

    
 

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    AGREEMENT

     

     

    Between

     

    BioCancell
Therapeutics Ltd.

    Beck
Science Center, 8 Hartom St.

    Jerusalem
97775, Israel

    (Hereinafter:
“BioCancell”)

     

    And
between

     

    Meir
Medical Center

    Kfar
Saba, Israel

     

    (Hereinafter:
“the Medical Center”)

     

     

    BioCancell
and the Medical Center shall be hereinafter collectively referred to in this
Agreement as “Parties”; each
one of which also referred to as “Party”.

     

    
      	
              Whereas

            	 	
              BioCancell
      has expressed its interest in carrying out, managing and funding the
      clinical trial the subject of which being “Phase 2b, Multicenter Trial of
      Intravesical DTA-H19/PEI in Patients with Intermediate-Risk Superficial
      Bladder Cancer”, bearing protocol no. BC-07-0l, a copy of which is
      attached as Appendix A hereto (hereinafter “the Trial”);
      and

            
	 	 	 
	
              Whereas

            	 	
              The
      Medical Center has declared it holds the proper facilities and staff
      required to perform the Trial, and that it is willing to put such
      facilities and staff at the disposal of BioCancell, for the purpose of
      performing the Trial; and

            
	 	 	 
	
              Whereas

            	 	
              The
      Parties agree that BioCancell shall maintain any and all management
      authorities with regard to the performance of the Trial in all of its
      stages; and

            
	 	 	 
	
              Whereas

            	 	
              BioCancell
      has agreed to pay the Medical Center the consideration, specified in
      Appendix C hereto, for the performance of all the undertakings of the
      Medical Center under this Agreement, all according to the terms and
      conditions of this Agreement

            


    

     

    Meir-final
agreement

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    NOW, THEREFORE, it is
hereby declared and agreed between the parties as follows:

     

    
      	1.	
              General

            


    

     

    
      	
            	1.1.	
              The
      preface and appendices to this Agreement constitute an integral part
      hereof.

            


    

     

    
      	
            	1.2.	
              Titles
      of the sections in this Agreement shall be used for terms of reference
      only, and could not be used for the interpretation of this
      Agreement.

            


    

     

    
      	
            	1.3.	
              This
      Agreement contains the entire understanding of the Parties and the
      Principle Investigator with respect to the subject matter hereof, and
      supersedes all prior or pre-existing negotiations, declarations,
      presentations, commitments and/or agreements, whether written or oral,
      whether explicit or implied, between the Parties and the Principle
      Investigator, with respect to such subject
  matter.

            


    

     

    
      	
            	1.4.	
              In
      the event of a contradiction between this Agreement and any of the terms
      of its appendices, the terms and conditions of this Agreement shall
      prevail.

            


    

     

    
      	
            	1.5.	
              Anything
      in this Agreement denoting the singular shall also denote the plural, and
      anything denoting the feminine gender shall also denote the masculine
      gender, and vice versa, insofar as no other meaning is inferred by the
      context.

            


    

     

    
      	2.	
              Appendices

            


    

     

    The
appendices to the Agreement are:

     

    
      	
            	2.1.	
              Appendix
      A: The Trial Protocol

            


    

     

    
      	
            	2.2.	
              Appendix
      B: The Trial Personnel Clearance

            


    

     

    
      	
            	2.3.	
              Appendix
      C: The Consideration

            


    

     

    
      	
            	2.4.	
              Appendix
      D: Schedule 4 of the Guidelines.

            


    

     

    
      	
            	2.5.	
              Appendix
      E: The Trial Documents and Related
Activities.

            


    

     

    
      	3.	
              Definitions

            


    

     

    In this
Agreement, the following terms shall have the specific meaning attributed to
them in the table below:

     

    
      	
              The
      Agreement

            	 	
              This
      agreement and its appendices.

            
	 	 	 
	
              Serious Adverse
      

            	 	
              As
      defined in the Trial Protocol and in the Guidelines.

            
	 	 	 
	
              Event
      Monitors

            	 	
              Any
      body or person/s nominated by, or representing BioCancell and/or any
      company of the BioCancell Group to monitor the Trial (i.e., conduct
      on-site audits for Good Clinical Practices compliance).

            
	 	 	 
	
              Completed
      CRF

            	 	
              A
      CRF having, according to the sole and absolute discretion of BioCancell
      and/or any third party appointed by BioCancell, no discrepancies in its
      details and no unanswered queries.

            
	 	 	 
	
              CRF

            	 	
              Case
      Report Forms containing any and all data of the Subjects, which has been
      gathered during the Trial. The CRF shall be in hardcopy
      format.

            
	 	 	 
	
              The End of the
      Trial

            	 	
              The
      point in time, in which a Completed CRF has been submitted to BioCancell
      by the Principal Investigator, as defined herein, for all the Subjects
      participating in the Trial, or the date of termination of the Trial
      according to the terms and conditions of the Agreement; the earlier of the
      two.

            


    

     

    Meir-final agreement

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

      

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

    
    

     

    
      	
              FDA

            	 	
              The
      United States of America Food and Drug Administration.

            
	 	 	 
	
              The
      Guidelines

            	 	
              Ministry
      of Health guidelines entitled “Clinical Trials of Human Subjects” as may
      be amended and modified from time to time.

            
	 	 	 
	
              The Helsinki
      Declaration

            	 	
              The
      1964 Declaration of Helsinki regarding the recommendations guiding
      physicians in bio-medical research involving human beings, as amended in
      Tokyo, 1975.

            
	 	 	 
	
              ICH-GCP

            	 	
              Harmonized
      Tripartite Guideline for Good Clinical Practice as may be amended and
      modified from time to time.

            
	 	 	 
	
              IND

            	 	
              Investigational
      New Drug Application (US code of Federal Regulations 21 CFR Part
      312).

            
	 	 	 
	
              Inspector/s

            	 	
              Any
      inspecting body legally authorized to perform inspections in clinical
      trials, including, inter alia, the MOH, FDA or any other state regulated
      medical authority.

            
	 	 	 
	
              Invention
      Rights

            	 	
              Any
      and all intellectual property rights, relating to the Trial Data or to the
      BioCancell Data, including, inter alia, the right to register and/or own
      any inventions stemming directly or indirectly from the Trial Data and/or
      the BioCancell Data. Without derogating from the generality of the above,
      the Invention Rights shall include, inter alia, patents, information,
      data, know-how, formulas, concepts, tests, drawings, specifications,
      applications, designs and trade secrets, methodologies, engineering and
      manufacturing processes and research processes, stemming directly or
      indirectly from the BioCancell Data and/or the Trial
  Data.

            
	 	 	 
	
              Investigator
      Brochure

            	 	
              A
      document, which is submitted along with the Trial Protocol to the relevant
      Helsinki Committee and FDA, and the content of which is outlined in the
      GCP Guidelines.

            
	 	 	 
	
              Medical Center Helsinki
      Committee Ministry of Health Approval

            	 	
              A
      committee appointed pursuant to the National Health Regulations and whose
      role is to approve any and all medical experiments on humans conducted by
      the Medical Center Approval from the Director General of the Ministry of
      Health, or whomever he/she has delegated the authority to for this
      purpose, for the performance of the Trial at the Medical Center, according
      to the National Health Regulations and the Guidelines.

            
	 	 	 
	
              Ministry of
      Health/MOH

            	 	
              The
      Israeli Ministry of Health.

            
	 	 	 
	
              National Health
      Regulations

            	 	
              Israel
      National Health Regulations (Clinical Trials on Human Subjects), 5741-1980
      as may be amended from time to time.

            
	 	 	 
	
              Publications

            	 	
              All
      publications, manuscripts, abstracts and papers relating directly
      or indirectly to the subject matter of the Trial, and which were initiated
      or composed directly or indirectly, in whole or in part, by the Principal
      Investigator and/or by the Medical Center and/or by any of the Trial
      Personnel.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
info@biocancell.com

                


        

      

    

     

    
      	
              The BioCancell
      Data

            	
              Any
      and all information provided by BioCancell or by the BioCancell Group to
      the Medical Center, Principal Investigator or any member of the Trial
      Personnel with regard to the Trial, including, without limitation, the
      Trial Protocol and the Investigator Brochure which shall be the sole
      property of the BioCancell Group.

            
	 	 
	
              The BioCancell Group
      

            	
              The
      group of companies consisting of BioCancell Group Therapeutics, Inc and
      BioCancell Therapeutics Ltd.

            
	 	 
	
              The
      Guidelines

            	
              Ministry
      of Health guidelines entitled “Clinical Trials of Human Subjects” as may
      be amended and modified from time to time.

            
	 	 
	
              The
      Product(s)

            	
              DTA-H19/PEI

            
	 	 
	
              The
    Reports

            	
              Any
      and all reports required by BioCancell, by any state regulated medical
      authority, or by any applicable laws, rules, regulations or
      guidelines.

            
	 	 
	
              The
    Subjects

            	
              A
      group of persons chosen by the Principal Investigator to participate in
      the Trial and who signed a written informed consent for the participation
      in the Trial, all according to the criteria established in the Trial
      Protocol.

            
	 	 
	
              The Trial
      Data

            	
              Any
      and all clinical data, technical information, records, files and materials
      relating to the Trial, including the Trial Documents, case report forms,
      source documents (such as subjects charts and physical notes), as well as
      other related data generated during or as a result of the Trial which
      shall be the sole property of the BioCancell Group.

            
	 	 
	
              Trial
      Documents

            	
              Any
      and all documents required by BioCancell, the MOH, the Medical Center or
      any applicable laws, rules, regulations or guidelines, for the initiation,
      performance and completion of the Trial; without derogating from the
      generality of the above, the Trial Documents shall include any and all
      documents specified in Appendix E to this Agreement.

            
	 	 
	
              Trial
      Personnel

            	
              The
      medical and administrative staff involved in the Trial, including those
      who shall be employed by the Medical Center and cleared according to the
      undertaking attached to this Agreement as Appendix B.

            
	 	 
	
              The Trial
      Protocol

            	
              A
      document that describes the objective(s), design, methodology, statistical
      considerations, and organization of the Trial. The Trial Protocol usually
      also gives the background and rationale for the trial, but these could be
      provided in other protocol referenced documents. Throughout this Agreement
      the term Trial Protocol refers to the protocol and its amendments, which
      are attached to this Agreement as Appendix
A.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    
      	4.	
              Precedent
      Condition

            


    

     

    The
Parties hereby agree and undertake that the Agreement shall not enter into
effect before both of following cumulative approvals have been granted
(hereinafter: “the Approvals”):

     

    
      	
            	4.1.	
              The
      approval of the Trial Protocol by Medical Center Helsinki Committee and
      the MOH, if such latter approval is required by the Guidelines;
      and

            


    

     

    
      	
            	4.2.	
              The
      approval of the Agreement in general, its budget and Appendix C in
      particular, by the MOH and the committee of engagement with commercial
      companies in accordance Section 9 of the Guidelines;
  and

            


    

     

    
      	
            	4.3.	
              The
      approval of the Trial Protocol, Investigator Brochure and related
      documents by the FDA.

            


    

     

    
      	5.	
              The Principal
      investigator

            


    

     

    
      	
            	5.1.	
              Dr.
      Ilan Leibovitch MD, of the Medical Center (hereinafter: “the Principal
      Investigator”)
      has agreed to serve as the principal investigator of the
      Trial.

            


    

     

    
      
        	
              	5.2.	
                
                  The
      Principal Investigator undertakes to perform the Trial in compliance with
      the following: (a) Trial Protocol, (b) the Guidelines, (c) the
      instructions and the terms specified in the approval of the Medical Center
      Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the
      applicable laws, rules and regulations regulating such studies which are
      applicable in Israel, (g) written instructions and prescriptions issued by
      BioCancell regarding the Trial and/or the Product, all as may be amended
      from time to time, and (h) the requirements in accordance with the FDA
      Form 1572 “Statement of
      Investigator.” Every PI at each site must sign this form for submission to
      the FDA.

                

              


      

       

      
        
          	
                	5.3.	
                  
                    The
      Principal Investigator has declared that he holds the professional ability
      and credentials required for performing the Trial in accordance with the
      Trial Protocol and any applicable laws, rules, regulations and guidelines,
      all as detailed above.

                  

                


        

         

      

    

    
      	
              
              

            	
              5.4.

            	
              In
      the event that the Principal Investigator, for any reason whatsoever,
      shall be unable to conduct the Trial, or shall cease to be available for
      the performance of the undertakings set forth in this Agreement, the
      Medical Center shall use its best efforts to appoint, within 20 days, a
      successor investigator whose identity shall be approved in advance by
      BioCancell (the “Successor
      Investigator”).
      Such Successor Investigator shall undertake all the duties and
      responsibilities of the Principal Investigator as detailed in the
      Agreement. Should the Medical Center not be able to appoint a Successor
      Investigator, or if the appointed Successor Investigator is not acceptable
      by BioCancell, either party shall be entitled to terminate this Agreement
      forthwith and without further
liability.

            


    

     

    
      
        	
              	5.5.	
                In
      the event of the replacement of the Principal Investigator, as described
      under this Section 5, the Principal Investigator shall have no claim
      towards BioCancell and/or the Medical Center and/or any third party acting
      on their behalf in direct or indirect connection with such
      replacement.

              


      

    

    
       

      Meir-final agreement

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
info@biocancell.com

                


        

      

    

     

    
      	6.	
              Medical Center
      undertaking

            


    

     

    
      	
            	6.1.	
              The
      Medical Center represents that it has the requisite skills, knowledge,
      experience and human resources to undertake and conduct the Trial in
      accordance with the provisions of this
  Agreement.

            


    

     

    
      	
            	6.2.	
              The
      Medical Center undertakes to perform the Trial in compliance with the
      following: (a) the Trial Protocol, (b) the Guidelines, (c) the
      instructions and the terms specified in the approval of the Medical Center
      Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the
      applicable laws, rules and regulations regulating such studies which are
      applicable in Israel, and (g) written instructions and prescriptions
      issued by BioCancell regarding the Trial and/or the Product, all as may be
      amended from time to time.

            


    

     

    
      	
            	6.3.	
              The
      Medical Center hereby undertakes to furnish BioCancell, the Principal
      Investigator and all of the Trial Personnel with the facilities and
      personnel necessary for the adequate performance of the Trial according to
      the terms and conditions of the Trial Protocol, and to fully collaborate
      with the Principal Investigator, BioCancell, and/or any other third party
      nominated by BioCancell, with regard to performing its duties
      hereunder.

            


    

     

    
      	7.	
              BioCancell
      Undertaking

            


    

     

    
      	
            	7.1.	
              BioCancell
      hereby undertakes to allow the Principal Investigator to use the
      BioCancell Data, exclusively for the purpose of performing the Trial,
      during the Term of This Agreement and according to the terms and
      conditions of this Agreement.

            


    

     

    
      	
            	 	
              
                The
      Principal Investigator shall strictly abide by any and all
      instructions given to him by BioCancell with regard to the BioCancell
      Data, while recognizing that BioCancell or any other company from the
      BioCancell Group was and shall remain, during the Term of this Agreement
      and thereafter, the sole and exclusive owner of any and all rights in the
      BioCancell Data and the Trial Data, and the use
    thereof.

              

            


    

     

    
      	
            	7.2.	
              BioCancell
      shall remunerate the Medical Center, the Principal Investigator and the
      Trial Personnel, according to the terms of Appendix C hereto, for all
      services rendered.

            


    

     

    
      	8.	
              Consideration

            


    

     

    In
consideration for the performance of all of the tasks, duties and undertakings
of the Principal Investigator, the Trial Personnel and the Medical Center under
this Agreement, BioCancell hereby undertakes to pay the Medical Center the
amount specified in Appendix C hereto, according to the installments, timetable
and manner specified therein.

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    
      	9.	
              Product
      Supply

            


    

     

    
      	
            	9.1.	
              BioCancell
      will, at its own expense, supply to the Medical Center all necessary
      quantities of the drugs to be used in the Trial, and only for the purposes
      as described in the Protocol. Any surplus shall be returned to BioCancell
      without delay, upon completion of the Trial or termination of this
      agreement for any reason whichever is the
  earlier.

            


    

     

    
      
        	
              	9.2.	
                The
      Medical Center will ensure that the Product is managed and stored in
      accordance with GCP and with any special instructions issued by
      BioCancell. The Medical Center will maintain proper records of receipts,
      dispensing and returns of the
Product.

              


      

    

     

    
      	
            	9.3.	
              BioCancell
      will continue to supply the Product after the termination of the Trial
      and/or Agreement to the patients participating in the trial in accordance
      with Appendix D.

            


    

     

    
      	10.	
              Trial Personnel Compliance and
      Clearance

            


    

     

    
      	
            	10.1.	
              The
      Medical Center and the Principal Investigator hereby undertake to exercise
      their best efforts so that the Trial Personnel shall abide by: (a) the
      Trial Protocol, (b) the Guidelines, (c) the instructions and the terms
      specified in the approval of the Medical Center Helsinki Committee, (d)
      the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules
      and regulations regulating such studies which are applicable in Israel,
      and (g) written instructions and prescriptions issued by BioCancell
      regarding the Trial and/or the Product, all as may be amended from time to
      time.

            


    

     

    
      	
            	10.2.	
              The
      Trial will also be conducted in accordance with the “Statement of
      Investigator” (FDA form no. 1572).

            


    

     

    
      	
            	10.3.	
              Trial
      Personal Clearance:

            


    

     

    
      	
              
              

            	
              10.3.1.

            	
              The
      Medical Center and the Principal Investigator shall deploy all possible
      efforts to see to it that none of the Trial Personnel (including the
      Principal Investigator and any other investigators) are debarred by the
      FDA or by the MOH in any capacity whatsoever, and that (1) none of the
      Trial Personnel appear in the FDA debarment list, detailing all firms or
      persons debarred pursuant to Section 306 (a) and (b) of the Federal Food,
      Drug, and Cosmetic Act (21 U.S.C. 335 (a) and (b)), as published in the
      Federal Registrar from time to time; and (2) none of the Trial Personnel
      are debarred according to the terms and conditions of the Israeli
      Physicians Ordinance [New Version], 1976 or pursuant to any other
      applicable law.

            


    

     

    
      	
            	
              10.3.2.

            	
              The
      Medical Center and the Principal Investigator shall provide BioCancell
      with the written confirmation thereof, in a form attached as Appendix B
      hereto.

            


    

     

    
      	11.	
              Compliance with the Trial
      Budget and Cooperation with BioCancell
    Subcontractors

            


    

     

    
      
        
          	
                	11.1.	
                  The
      Medical Center and the Principal Investigator hereby undertake to perform
      the Trial in accordance with, the budget of the Trial, as such term is
      derived from
      Appendix C hereto (hereinafter: “the Trail
      Budget”)
      and not to deviate therefrom without the prior written approval of
      BioCancell in relation
thereto.

                


        

      

    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    
      	
            	11.2.	
              The
      Medical Center hereby undertakes that any deviation from the Trial Budget
      without the prior written consent of BioCancell shall be born by the
      Medical Center.

            


    

     

    
      	
            	11.3.	
              The
      Medical Center and the Principal Investigator hereby undertake to fully
      cooperate with any and all sub-contractors nominated by BioCancell for the
      purpose of the Trial, including, inter alia, clinical research
      organizations, logistics companies, laboratories,
  etc.

            


    

     

    
      	12.	
              Trial
      Documents

            


    

     

    
      	
            	12.1.	
              The
      Principal Investigators shall prepare and submit the Trial
      Documents.

            


    

     

    
      	
            	12.2.	
              The
      Principal Investigator shall perform all the activities specified in
      Appendix E hereto.

            


    

     

    
      	
            	12.3.	
              Any
      and all amendments to the Trial Protocol shall be performed only after
      securing the approval of BioCancell and the competent regulatory
      authority.

            


    

     

    
      	13.	
              Confidentiality

            


    

     

    
      	
            	13.1.	
              The
      Parties and the Principal Investigator hereby agree and undertake that
      they are aware that the BioCancell Data and the Trial Data (hereinafter,
      jointly and severally “the Confidential
      Information”)
      are confidential information, and that BioCancell has disclosed such
      Confidential Information to the Medical Center and Principal Investigator
      for the sole purpose of conducting the
Trial.

            


    

     

    
      	
            	13.2.	
              The
      Parties and the Principal Investigator hereby agree and undertake that
      they are aware that the Confidential Information is the sole and exclusive
      property of BioCancell and/or any other company from the BioCancell Group.
      Accordingly, The Principal Investigator shall retain the Confidential
      Information under the strictest safeguarding and not use, disclose or
      divulge the Confidential Information in part or in whole, directly or
      indirectly, for a period of seven (7)
years.

            


    

     

    
      	
            	13.3.	
              The
      Medical Center and the Principal Investigator shall maintain the
      confidentiality of the Confidential Information using the same degree of
      care used by them in relation to their own confidential information, and
      shall without limitation, keep the Confidential Information in a safe and
      separate place and not make any copies thereof (whether in hardcopy or
      electronic file) unless first receiving BioCancell’s written
      consent.

            


    

     

    
      	
            	13.4.	
              The
      Medical Center and the Principal Investigator hereby further undertake to
      limit access to the Confidential Information to the Trial Personnel and
      any third parties on a “need to know basis” only, and such Trial Personnel
      and third parties to accept, in writing, the undertaking of the Principal
      Investigator in relation to the Confidential Information under this
      Agreement, as a condition precedent for receipt of any part of the
      Confidential Information.

            


    

     

    
      
        Meir-final agreement

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    
      	
            	13.5.	
              At
      the request of BioCancell, the Medical Center and the Principal
      Investigator shall forthwith return to BioCancell the Confidential
      Information or any part thereof.

            


    

     

    
      	
            	13.6.	
              The
      Medical Center and the Principal Investigator hereby state that they are
      aware of the fact that any unauthorized disclosure or use of the
      Confidential Information shall cause immediate and/or irreparable injury
      to BioCancell, and that BioCancell cannot be adequately compensated for
      such injury in monetary damages. Thus, in order to safeguard BioCancell
      from any possible breach of confidentiality, the Principal Investigator
      and the Medical Center hereby undertake that BioCancell would be permitted
      to obtain, from any Court or Tribunal, any temporary or permanent
      injunction relief, necessary to prevent such unauthorized disclosure or
      use or peril thereof, and hereby renounce filing and/or submitting any
      objection to any request by BioCancell or by any company from the
      BioCancell Group, relating to such temporary or permanent
      injunction.

            


    

     

    
      	
            	13.7.	
              For
      the avoidance of any doubt, it is hereby clarified that such an
      undertaking is supplementary to and will not prejudice any right or
      remedy, which is or shall be available to BioCancell under any applicable
      law or agreement.

            


    

     

    
      	
            	13.8.	
              The
      Medical Center and the Principal Investigator hereby undertake to exercise
      their best efforts to see to it that the Trial Personnel shall abide by
      the undertakings set forth in this Section
13.

            


    

     

    
      	
            	13.9.	
              In
      the event that the Medical Center and the Principal Investigator are
      required by law, regulation, rule, act or order of any governmental
      authority or agency to disclose Confidential Information, they shall be
      entitled to do so provided that it shall reasonably attempt to first
      notify BioCancell of any such required disclosure, so that BioCancell may
      seek an appropriate protective order, and limit such disclosure as far as
      is possible under applicable law. Such disclosure shall, however, not
      relieve the Medical Center and the Principal Investigator of their other
      obligations contained herein.

            


    

     

    
      	14.	
              Invention
      Rights

            


    

     

    
      	
            	14.1.	
              The
      Medical Center and the Principal Investigator hereby acknowledge that the
      idea and initiative for the Trial were exclusively those of BioCancell,
      and that the involvement of the Medical Center and the Principal
      Investigator in the Trial is strictly the consequence of their nomination
      by BioCancell.

            


    

     

    
      	
            	14.2.	
              The
      Parties and the Principal Investigator hereby irrevocably agree and
      undertake that the Confidential Information, except for medical records of
      the Subjects, is the exclusive property of BioCancell, may be freely
      utilized by BioCancell in any manner it sees fit. Notwithstanding the
      above, BioCancell shall have the right to review Subjects’ medical records
      to verify entries in the CRF’s. BioCancell hereby undertakes full
      responsibility to ensure the safekeeping of patients’ confidentiality and
      personal data and shall be fully responsible for taking every measure to
      apply this commitment.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

       

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
info@biocancell.com

                


        

      

    

     

    
      	
            	14.3.	
              The
      Parties and the Principal Investigator hereby irrevocably agree and
      undertake that the Invention Rights shall be the absolute and exclusive
      property of BioCancell and that BioCancell shall have unrestricted free
      right to use such Invention Rights.

            


    

     

    
      	
            	14.4.	
              The
      Medical Center and the Principal Investigator hereby undertake to disclose
      to BioCancell any and all applicable information relating to Invention
      Rights and exercise their best efforts with regards to registration of the
      Inventions Rights on the name of BioCancell and/or a name designated in
      writing by BioCancell, if and to the extent requested to do so by
      BioCancell.

            


    

     

    
      	
            	14.5.	
              If
      by operation of law or for any reason, any Invention Rights to be owned by
      BioCancell pursuant to this Section 14 are not automatically deemed
      proprietary BioCancell upon their creation, the Medical Center and the
      Principal Investigator hereby further undertake to cause the Trial
      Personnel to, irrevocably grant and assign all such intellectual property
      rights to BioCancell. The Medical Center warrants that it has and will
      continue to have agreements with its personnel, including any Trial
      Personnel, to effectuate the terms of this section and it shall enforce
      such agreements to provide BioCancell with the benefit of this
      section.

            


    

     

    
      	15.	
              Inspections

            


    

     

    
      	
            	15.1.	
              The
      Medical Center and the Principal Investigator hereby undertake to allow
      the Monitors to perform monitoring visits in all sites related to the
      Trial, during or after the Trial, and assist the Monitors in their duties.
      For the avoidance of doubt, it is hereby clarified that the Monitors shall
      be entitled to monitor and/or inspect among others the Trial Documents and
      Trial Data as well as to insure compliance with the Trial
      Protocol.

            


    

     

    
      	
            	15.2.	
              The
      Medical Center and the Principal Investigator hereby undertake to allow
      the Inspectors to perform inspections of all sites related to the Trial,
      during or after the Trial (and each such inspection shall hereinafter be
      referred to as “an Inspection”), and to assist the Inspectors in their
      duties, if and to the extent requested to do so by the
      Inspectors.

            


    

     

    
      	
            	15.3.	
              The
      Medical Center and the Principal Investigator shall immediately inform
      BioCancell in the event of an Inspection and/or upon gaining knowledge of
      any intention to perform an Inspection. The Medical Center and the
      Principal Investigator shall provide BioCancell with copies of any
      inquiries, correspondence or communications to or from any such
      Inspectors.

            


    

     

    
      	16.	
              Publications

            


    

     

    
      	
            	16.1.	
              BioCancell
      covenants that it will not at any time, without first obtaining the
      consent in writing of the Medical Center (which consent may by refused or
      granted in its absolute discretion), use the Medical Center’s name or the
      name of the Principal Investigator or otherwise disclose the fact of their
      involvement in the performance of the Trial in any advertising, publicity
      or publication.

            


    

    
       

      Meir-final agreement

      

        
          
            
            

          

          
            
            

            
              

            

          

           

        

      

    

    
    

      

      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    However,
BioCancell may use the name of the Medical Center and/or the Principal
Investigator for listing the Trial on clinicaltrials.gov.

     

    
      	
            	16.2.	
              Publications
      of the Trial and/or its results, in whole or in part, shall be within the
      sole and absolute discretion of BioCancell. The Medical Center, the
      Principal Investigator or the Trial Personnel, and any employees and/or
      officers and/or representatives of any of the foregoing shall not publish
      or refer to the Trial and/or its results, in whole or in part, without
      obtaining the prior consent BioCancell in writing. BioCancell reserves the
      right to reject any such request, at its sole discretion. For the
      avoidance of doubt BioCancell has the right, at all times, to publish any
      article or data generated from the services rendered under this
      Agreement.

            


    

     

    
      	
            	16.3.	
              Without
      derogating from this Section 16, BioCancell hereby undertakes to abide by
      the rules of publications issued by the MOH and set forth in Section 2 of
      Appendix D attached hereto.

            


    

     

    
      	17.	
              Reports

            


    

     

    
      	
            	17.1	
              The
      Medical Center and the Principal Investigator hereby undertake to submit
      the Reports to BioCancell and/or competent authorities, whether Israeli or
      foreign.

            


    

     

    
      	
            	17.2.	
              The
      Medical Center and the Principal Investigator hereby undertake to disclose
      in the Reports any and all data provided to them by BioCancell, in
      accordance with any applicable laws, rules, regulations and guidelines,
      including, inter alia, safety data.

            


    

     

    
      	
            	17.3.	
              The
      Medical Center will cause the Principal Investigator to provide
      BioCancell, within 45 (forty five) days of the end of each period of three
      (3) months during the period of the Trial, with a written report on the
      progress of the Trial in the said
period.

            


    

     

    
      	
            	17.4.	
              45
      (forty five) days following the End of the Trial, the Principal
      Investigator shall submit to BioCancell a summary report, which shall
      include, in a full and detailed manner, a declaration regarding the
      activities performed during the Trial and the results obtained
      therein.

            


    

     

    
      	18.	
              Serious Adverse
      Event

            


    

     

    
      
        	
              	18.1.	
                In
      the event one or more of the Subjects sustains any Serious Adverse Event
      related to the Trial, the Principal Investigator shall inform BioCancell
      and the Medical Center Helsinki Committee and/or the Medical Center
      management and/or the authorized national health
    authorities.

              


      

    

     

    
      	
            	18.2.	
              The
      Principal Investigator shall report such Serious Adverse Event in the
      timetable and manner prescribed in the Trial Protocol and
      Guidelines.

            


    

     

    
      	
            	18.3.	
              In
      the occurrence of a Serious Adverse Event the Principal Investigator and
      the Medical Center Helsinki Committee shall be entitled to immediately
      cease the performance of the Trial, pending a prior notice of at least 24
      hours to BioCancell regarding such decision and its
    execution.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

       

    

     

    
      
        
          
            	
                    

                  	
                    8
      Hartom St, Jerusalem Israel 97775

                    Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                    www.biocancell.com
      info@biocancell.com

                  


          

        

      

    

     

    
      	
            	18.4.	
              In
      the occurrence of a Serious Adverse Event BioCancell will immediately take
      all measures at their disposal to evaluate the risk to the other patients
      and will instruct the Principal Investigator which measures to take with
      regard to that risk.

            


    

     

    
      	
            	18.5.	
              BioCancell
      has an obligation, as the trial sponsor, to notify each investigator of
      any Serious Adverse Events that are reported by any site during the trial
      that are submitted to the FDA in a safety report. Each Principal
      Investigator is obligated to provide these reports to the appropriate
      Helsinki Committee.

            


    

     

    
      	19.	
              The
      Legal Status of the Medical Center and the Principal
      Investigator

            


    

     

    
      	
            	19.1.	
              The
      Parties and the Principal Investigator hereby agree that the relationship
      between BioCancell, on one hand, and the Medical Center and the Principal
      Investigator, on the other hand, are that of a client and an independent
      contractor, with the Medical Center and the Principal Investigator lacking
      any capacity whatsoever to legally bind BioCancell to a relationship of
      employer-employee, principal-agent or any other legal relationship
      differing from that of a client and an independent
    contractor.

            


    

     

    
      	
            	19.2.	
              Should
      any court of law rule in a manner opposed to Section 19.1 above, the
      Medical Center and the Principal Investigator, jointly and severally,
      hereby undertake to indemnify BioCancell with regards to the respective
      damage caused by each of them separately due to such a
    ruling.

            


    

     

    
      	20.	
              Term and
      Termination

            


    

     

    
      	
            	20.1.	
              This
      Agreement shall be in full force and effect as of the latter of either:
      (a) the date of its execution by the last Party or (b) the date the
      Approvals have been granted; and until the End of the Trial (and the
      period in which this Agreement shall be in full force and effect shall be
      referred to in this Agreement as “the Term of this
      Agreement”).

            


    

     

    
      	
            	20.2.	
              The
      Parties may bring this Agreement to an early end at any time, in writing,
      by prior notice of at least 30 (thirty) days, upon the occurrence of one
      (or more) of the following events:

            


    

     

    
      	
            	
              20.2.1.

            	
              The
      MOH has voided its approval granted for the performance of the Trial or
      has conditioned the approval by conditions which the Medical Center and/or
      the Principal Investigator, as the case may be, have notified BioCancell
      that they are unable to comply
with.

            


    

     

    
      	
            	
              20.2.2.

            	
              The
      FDA has placed the Trial on clinical
hold.

            


    

     

    
      	
            	
              20.2.3.

            	
              BioCancell
      decides upon its sole and absolute discretion to bring the Trial to an
      end. For the sake of good order, the Parties and the Principal
      Investigator hereby state and undertake that they are aware, and agree,
      that BioCancell is entitled to terminate this Agreement, upon its sole and
      absolute discretion, at any moment whatsoever; and in this case no party
      hereto shall have any claim whatsoever towards BioCancell and/or any other
      company from the BioCancell Group with regard to such early
      termination.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    
      	
            	
              20.2.4.

            	
              A
      Party and/or the Principal Investigator is found to be in breach of this
      Agreement and does not cure such breach within a period of 30 (thirty)
      days following receipt of a notice in writing from any of the other
      Parties in relation thereto.

            


    

     

    
      	
            	
              20.2.5.

            	
              A
      Party and/or the Principal Investigator enter into bankruptcy or
      liquidation proceedings or a receiver is appointed over part or all of
      their assets, and such proceedings are not ceased within a period of 45
      (forty five) days following receipt by such Party of a written notice in
      relation thereto from any or all of the other
  Parties.

            


    

     

    
      	
            	20.3.	
              In
      the event of termination of this agreement the Parties and the Principal
      Investigator shall bring the Trial to an end as
  follows:

            


    

     

    
      	
            	
              20.3.l.

            	
              Any
      and all Confidential Information and remaining supply of Product shall be
      returned to BioCancell.

            


    

     

    
      	
            	
              20.3.2.

            	
              The
      Parties and the Principal Investigator shall cooperate in swiftly
      dispersing the Subjects and Trial Personnel, if the need arises, while
      preserving the latest Trial Data and providing as many Completed CRF’s as
      possible, and all to the satisfaction of
  BioCancell.

            


    

     

    
      	
            	20.4.	
              The
      obligation of the Parties and the Principal Investigator pursuant to
      sections 13, 14, 16, 17, and 21 shall survive termination of this
      Agreement.

            


    

     

    
      	21.	
              Insurance and
      Indemnification

            


    

     

    
      	
            	21.1.	
              BioCancell
      has agreed to insure, in accordance with the terms and conditions set
      forth in Appendix D attached hereto, the Subjects, the Trial Personnel,
      the Principal Investigator and the Medical
  Center.

            


    

     

    
      	
            	21.2.	
              BioCancell
      has agreed to indemnify the Trial Personnel the Principal Investigator and
      the Medical Center according to the terms of Sub-Section 21.3 below
      (hereinafter each of them shall also be referred to as: the “Indemnitee”) for damages arising as a
      direct result of their involvement in the performance of the Trial
      (hereinafter: the “Damages”), provided
      that the damages are not as a result of an expected side effect of the
      Products and subject to the conditions detailed
  herein:

            


    

     

    
      	
            	
              21.2.1.

            	
              The
      Damages are not caused as a result of negligence or misconduct of the
      Indemnitee;

            


    

     

    
      	
            	
              21.2.2.

            	
              The
      Indemnitee performed the Trial in accordance with the Trial protocol and
      the additional requirements set in this
  Agreement;

            


    

     

    
      	
            	21.3.	
              Promptly
      after receipt by the Indemnitee of a notice of the commencement of any
      claim, action, suit, proceeding or investigation in respect of which
      indemnity may be sought pursuant to this Section 21 (hereinafter: the
      “Claim”), the Indemnitee shall
      provide a notice to BioCancell, in writing, describing in reasonable
      detail the facts and circumstances upon which the asserted Claim for
      indemnification is based, and shall thereafter keep BioCancell reasonably
      informed with respect thereto. BioCancell shall have the right to assume
      the defense of any Claim, at its sole discretion. In any event, the
      Indemnitee shall cooperate with BioCancell in the defense of any Claim for
      which BioCancell assumes the defense BioCancell shall not be liable for
      the settlement by the Indemnitee of any Claim affected without the consent
      of BioCancell. BioCancell shall be entitled to enter into any settlement
      of a Claim at its sole discretion. BioCancell may not assume the blame or
      liability of the Medical Center, Trial Personnel or the PI without their
      prior written consent.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

       

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    
      	22.	
              Notices

            


    

     

    
      	
            	22.1.	
              Notices
      to be given by one Party to another shall be in the English language, and
      shall be deemed property given if reduced to writing and transmitted to
      the Party’s address appearing on the first page of this Agreement, by air
      courier or by certified registered mail - all to be effective 3 (three)
      days after their sending date, or by facsimile with confirmation receipt -
      to be effective at the first business day following the date of
      transmission.

            


    

     

    
      	
            	22.2.	
              However,
      a notice shall be considered properly given, only in case a copy thereof
      was communicated as follows:

            


    

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          	
                                  Notice
      to BioCancell

                                	 	
                                  Notice
      to Medical Center

                                
	
                                  BioCancell
      Therapeutics Ltd.

                                	 	
                                  /s/
      Victor Vishlitzky

                                
	
                                  Beck
      Science Center, 8 Hartom St.

                                	 	
                                  
                                    VICTOR
      VISHLITZKY M.D.

                                  

                                
	
                                  Jerusalem,
      97775 Israel

                                	 	
                                  
                                    DEPUTY
      DIRECTOR

                                  

                                
	
                                  Attn:
      Ran Vigdor

                                	 	
                                  MEIR
      GENERAL HOSPITAL

                                
	
                                  Director,
      Strategic Alliances

                                	 	
                                  KFAR
      SABA, ISRAEL

                                
	
                                  Telephone:  
      +972-2-548-6555

                                	 	
                                  Telephone:

                                
	
                                  Facsimile:  +972-2-548-6550

                                	 	
                                  Facsimile:

                                


                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      	
            	22.3.	
              The
      addresses of the Parties, listed in page 1 of this Agreement, shall be
      subject to any change of such address notified in writing by one Party to
      the other, according to the procedure stipulated in this
      Section.

            


    

     

    
      	23.	
              Miscellanies

            


    

     

    
      	
            	23.1.	
              Expenses
      of the Parties, Each Party and the Principal Investigator shall bear all
      its own expenses, including the expenses of its attorneys, in connection
      with the negotiation, execution and performance of this
      Agreement.

            


    

     

    
      	
            	23.2.	
              Waiver
      and forbearance. No rights of any Party shall be prejudiced or restricted
      by any indulgence or forbearance, to any other person or entity, and no
      waiver by any Party in respect of any breach shall operate as a waiver in
      respect of any subsequent breach.

            


    

     

    
      	
            	23.3.	
              Governing
      law and jurisdiction. This Agreement shall be exclusively governed by the
      Laws of the State of Israel. Any and all disputes arising hereunder shall
      be resolved by a competent court having jurisdiction over such matters in
      the Tel-Aviv Jaffa District, Israel

            


    

     

    
      	
            	23.4.	
              Assignment.
      This Agreement shall not be assigned, without the prior written consent of
      all of the other Parties, save for an assignment of rights by BioCancell
      to any company within the BioCancell
Group.

            


    

     

    Meir-final agreement

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          	
                  

                	
                  8
      Hartom St, Jerusalem Israel 97775

                  Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                  www.biocancell.com
      info@biocancell.com

                


        

      

    

     

    
      	
            	23.5.	
              Counterparts.
      This Agreement and any amendment hereto may be executed in multiple
      counterparts, each of which shall be deemed an original agreement and all
      of which shall constitute one and the same
  agreement.

            


    

     

    
      	
            	23.6.	
              Amendments.
      Modification or amendment to this Agreement shall only be valid if
      performed by a written instrument, signed by all Parties to this
      Agreement.

            


    

     

    
      	
            	23.7.	
              Severability.
      If any provision of this Agreement is determined by a court of competent
      jurisdiction to be invalid, illegal, or unenforceable, that determination
      shall not affect any other provision of this Agreement, and each such
      other provision shall be construed and enforced as if the invalid,
      illegal, or unenforceable provision were not contained
    herein.

            


    

     

    [Remainder of page left
intentionally blank. Signature page follows.]

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

       

    

    
       

      
        
          
            	
                    

                  	
                    8
      Hartom St, Jerusalem Israel 97775

                    Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                    www.biocancell.com
      info@biocancell.com

                  


          

        

      

    


    IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed and each of the undersigned hereby warrants and represents that he or
she has been and is, on the date of this Agreement, duly authorized by all
necessary and appropriate action to execute this Agreement.

    


    IN
WITNESS WHEREOF, the parties have executed this Agreement as at the date first
above written:

    


      
        	
                BioCancell
      Therapeutics Ltd.

              	
                Meir
      Medical Center

              
	 	 
	
                By:
      /s/ Avi
      Barak

              	
                By:
      /s/ Victor
      Vishlitzky M.D.

              
	 	 
	
                Print
      Name: Avi Barak

              	
                Print
      Name: Victor Vishlitzky
      M.D.

              
	 	 
	
                Title:
      CEO

              	
                Title:
      Deputy Director 

                  Meir
      General Hospital 

                    Kfar
      Saba, Israel

                  

                

              
	
                 

              	
                 

              
	
                By:
      /s/ Patricia
      Ohana

              	
                By:_____________________

              
	 	 
	
                Print
      Name: Patricia Ohana

              	
                Print
      Name:_______________

              
	 	 
	
                Title:
      VP Clinical Development

              	
                Title:____________________

              


      

    

     

    I the
undersigned, Dr. Ilan Leibovitch MD, hereby declare and confirm that I have read
and understood the Agreement. I hereby agree to be appointed as the Principal
Investigator of the Trial on behalf of the Medical Center, and accept and
undertake to comply with all the terms, conditions, provisions, instructions and
stipulations set forth in the Agreement, including without limitation,
provisions referring to the Parties.

    
      	 	 	 	 
	/s/ Ilan Leibovitch
M.D.	 	 	 
	The Principal
      Investigator	 	 	
            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      
         

        
          
            
              	
                      

                    	
                      8
      Hartom St, Jerusalem Israel 97775

                      Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                      www.biocancell.com
      info@biocancell.com

                    


            

          

        

      

    

     

    Appendix
A

    


    The Trial
Protocol

    See attached
separately

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          
            	
                    

                  	
                    8
      Hartom St, Jerusalem Israel 97775

                    Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                    www.biocancell.com
      info@biocancell.com

                  


          

        

      

    

     

    Appendix
B

     

    The Trial Personnel
Clearance

    An Undertaking with regard
to a Clinical Trial’s Personnel

    


    We, the
undersigned, hereby warrant and undertake in relation of clinical trial bearing
protocol number BC-07-01, researching “Phase 2b, Multicenter Trial of
Intravesical DTA-H19/PEI in Patients with Intermediate-Risk Superficial Bladder
Cancer”, that we have not, we do not and we will not use nor employ, in any
capacity, the services of any person debarred under Section 306 (a) or (b) of
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 335 (a) and (b)), or
debarred under the Israeli Physicians Ordinance [New Version], 1976 or pursuant
to any other applicable law.


    
      	 	 	 	 
	/s/ Ilan
      Leibovitch	 	 	/s/ Victor
      Vishlitzky
	
              
    	 	 	
              
    
	
               

            	
              8.11.07

            	 
	 	 Date	 


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          
            	
                    

                  	
                    8
      Hartom St, Jerusalem Israel 97775

                    Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                    www.biocancell.com
      info@biocancell.com

                  


          

        

      

    

     

    Appendix C

     

    The
Consideration

     

    1. Terms and
Definitions

     

    In this
Appendix C terms shall have the meaning assigned to them in the Agreement. The
following terms shall have the meanings assigned to them hereunder.

     

    
      
        	
                Complete
      Screening

              	 	
                A
      Screening of a Subject in which all examinations and/or tests and/or
      treatment and/or evaluations included in the Screening process, as
      detailed in the Trial Protocol, have been performed and the data collected
      and registered in the CRF

              
	 	 	 
	
                Complete Evaluation Visit or
      Complete Treatment Visit

              	 	
                A
      Visit of a Participating Subject in which all examinations and/or tests
      and/or treatment and/or evaluations scheduled for the visit have been
      performed, as detailed in the Trial Protocol, and the data collected and
      registered in the CRF

              
	 	 	 
	
                Evaluation
      Visit

              	 	
                Any
      Visit, as defined below, of visits 7, 11, 15, and 19 as these visits are
      numbered and defined in the Trial Protocol.

              
	 	 	 
	
                Participating
      Subject

              	 	
                A
      Subject who that has undergone Screening, as defined below, and was
      determined to meet the requirements specified in the Trial protocol and
      who is participating in the Trial according to the terms and conditions of
      the Trial Protocol

              
	 	 	 
	
                Screening

              	 	
                A
      series of tests and examinations as defined in table 4 of the Trial
      Protocol designed to evaluate a Subject's suitability for participating in
      the Trial, as detailed in the Trial Protocol.

              
	 	 	 
	
                Treatment
      Visit

              	 	
                Any
      Visit, as defined below, of visits 1-6, 8-10, 12-14, and 16-18 as these
      visits are numbered and defined in the Trial Protocol.

              
	 	 	 
	
                Visits

              	 	
                Any
      one of the scheduled nineteen (19) visits of a Participating Subject as
      detailed in table 4 and 5 of the Trial
Protocol.

              


      

    

     

    
      	2.	
              The
      Consideration

            


    

     

    
      	
            	2.1.	
              In
      consideration for the performance, in good faith, by the Principal
      Investigator and the Medical Center, of all of their undertakings under
      this Agreement, BioCancell hereby undertakes to pay to the Medical Center
      the following amounts:

            


    

     

    
      
        
          	
                  Visit
      #

                	
                  Procedure

                	
                  Costs
      of procedure (NIS)

                	
                  Totals
      costs per visit

                
	 	 	 	 
	
                  Screening

                	
                  Urine
      cytology 

                  Video
      cystoscopy

                  Histology
      & Pathology

                  Doctor’s
      fee

                  Study
      nurse

                  Study
      coordinator

                  TUR

                	
                  140

                  370

                  180

                  1,000

                  250

                  250

                  960

                	
                   

                   

                   

                   

                   

                  3,150

                
	 	 	 	 


        

        
           

          Meir-final agreement

           

        

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

         

        
          
            
              
                	
                        

                      	
                        8
      Hartom St, Jerusalem Israel 97775

                        Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                        www.biocancell.com
      info@biocancell.com

                      


              

            

          

        

         

        
          	
                  Visit
      # 1

                	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	
                  750

                  250

                  250

                	
                  1,250

                
	 	 	 	 
	
                  Visit
      # 2

                	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	
                  750

                  250

                  250

                	
                  1,250

                
	 	 	 	 
	
                  Visit
      # 3

                	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	
                  750

                  250

                  250

                	
                  1,250

                
	 	 	 	 
	
                  Visit
      # 4

                	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	
                  750
      

                  250

                  250

                	
                  1,250

                
	 	 	 	 
	
                  Visit
      # 5

                	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	
                  750
      

                  250

                  250

                	
                  1,250

                
	 	 	 	 
	
                  Visit
      # 6

                	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	
                  750
      

                  250

                  250

                	
                  1,250

                
	 	 	 	 
	
                  Visit
      # 7

                	
                  Urine
      cytology 

                  Video
      cystoscopy

                  Histology
      & Pathology

                  Doctor’s
      fee

                  Study
      nurse

                  Study
      coordinator

                  TUR

                	
                  140

                  370

                  180

                  500

                  250

                  250

                  960

                	
                  2,650

                
	 	 	 	 
	
                  Total per first treatment
      period

                	 	
                  13,300

                
	 	 	 
	
                  Visit
      # 8

                	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	
                  750
      

                  250

                  250

                	
                  1,250

                
	 	 	 	 
	
                  Visit
      # 9

                	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	
                  750
      

                  250

                  250

                	
                  1,250

                
	 	 	 	 


        

        
           

          Meir-final agreement

           

        

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

         

        
          
            
              
                	
                        

                      	
                        8
      Hartom St, Jerusalem Israel 97775

                        Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                        www.biocancell.com
      info@biocancell.com

                      


              

            

          

        

         

        
          	
                  Visit
      # 10

                	 	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	 	
                  750
      

                  250

                  250

                	 	
                  1,250

                
	 	 	 	 	 	 	 
	
                  Visit
      # 11

                	 	
                  Urine
      cytology 

                  Video
      cystoscopy

                  Doctor’s
      fee

                  Study
      nurse 

                  Study
      coordinator

                	 	
                  140

                  370

                  500

                  250

                  250

                	 	
                  1,510

                
	 	 	 	 	 	 	 
	
                  Visit
      # 12

                	 	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	 	
                  750
      

                  250

                  250

                	 	
                  1,250

                
	 	 	 	 	 	 	 
	
                  Visit
      # 13

                	 	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	 	
                  750
      

                  250

                  250

                	 	
                  1,250

                
	 	 	 	 	 	 	 
	
                  Visit
      # 14

                	 	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	 	
                  750
      

                  250

                  250

                	 	
                  1,250

                
	 	 	 	 	 	 	 
	
                  Visit
      # 15

                	 	
                  Urine
      cytology 

                  Video
      cystoscopy

                  Doctor’s
      fee

                  Study
      nurse 

                  Study
      coordinator

                	 	
                  140

                  370

                  500

                  250

                  250

                	 	
                  1,510

                
	 	 	 	 	 	 	 
	
                  Visit
      # 16

                	 	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	 	
                  750
      

                  250

                  250

                	 	
                  1,250

                
	 	 	 	 	 	 	 
	
                  Visit
      # 17

                	 	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	 	
                  750
      

                  250

                  250

                	 	
                  1,250

                
	 	 	 	 	 	 	 
	
                  Visit
      # 18

                	 	
                  Doctor’s
      fee

                  Study
      nurse (Drug administration & blood sampling)

                  Study
      coordinator

                	 	
                  750
      

                  250

                  250

                	 	
                  1,250

                
	 	 	 	 	 	 	 


        

         

          Meir-final agreement

           

        

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

         

        
          
            
              
                	
                        

                      	
                        8
      Hartom St, Jerusalem Israel 97775

                        Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                        www.biocancell.com
      info@biocancell.com

                      


              

            

          

        

         

        
          	
                  Visit
      # 19

                	 	
                  Urine
      cytology 

                  Video
      cystoscopy

                  Doctor’s
      fee

                  Study
      nurse 

                  Study
      coordinator

                	 	
                  140

                  370

                  500

                  250

                  250

                	 	
                  1,510

                
	 	 	 	 	 	 	 
	
                  Total
      per continued treatment period (if no recurrence)

                	 	 	 	 	 	
                  15,780

                
	 	 	 	 	 	 	 
	
                  Total
      per first treatment period & continued treatment
period

                	 	 	 	
                  13,300
      + 15,780

                	 	
                  29,080

                
	 	 	 	 	 	 	 
	
                  General

                	 	
                  Unscheduled
      Histology & Pathology (If applicable)

                	 	
                  180

                	 	
                  180

                
	 	 	 	 	 	 	 
	
                  General

                	 	
                  Unscheduled
      Video cystoscopy

                	 	
                  370

                	 	
                  370

                
	 	 	 	 	 	 	 
	
                  General

                	 	
                  Unscheduled
      TUR

                	 	
                  960

                	 	
                  960

                
	 	 	 	 	 	 	 
	
                  Pharmacy

                	 	 	 	
                  500
      US $

                	 	
                  500
      US $

                


        

      

    

     

    * Blood
work and Urine analysis will be perform by an external central Lab (the costs
will be covered by the sponsor).

     

    
      
        	3.	
                Limitation of
      Payments

              


      

    

     

    
      	
            	3.1.	
              For
      the avoidance of doubt, it is hereby declared and agreed that BioCancell
      shall not pay any additional payments or any other amounts, which are not
      clearly mentioned and specified in section 2
  above.

            


    

     

    
      
        	
              	3.2.	
                It
      is further clarified that the amounts specified in section 2 above include
      payment by BioCancell for all services rendered from the Medical Center
      including but not limited to office services, Trial Personal required for
      performing the Trial including the Principal Investigator, physicians,
      nurses, receptionists and study coordinator, use of the Medical Center's
      facilities, and all tests, procedures, examinations and evaluations as
      detailed in the Trial
protocol.

              


      

    

    
       

    

    
      
        
          	
                	3.3.	
                  The
      considerations do not include cost of analysis of hematology and chemistry
      samples which will be performed by BioCancell's
      sub-contractor/s.

                


        

      

    

     

    
      	4.	
              Terms of
      Payment

            


    

     

    
      	
            	4.1.	
              The
      Medical Center shall send an invoice at the end of each calendar quarter
      (31/3, 30/6, 30/9, and 31/12) detailing the Complete Screening, Complete
      Treatment Visits and Complete Evaluation Visits (together hereinafter:
      “Complete
      Visits”)
      performed as well as on which Subjects or Participating Subjects the
      relevant Complete Visit was
performed.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

       

    

     

    
      
        
          
            	
                    

                  	
                    8
      Hartom St, Jerusalem Israel 97775

                    Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                    www.biocancell.com
      info@biocancell.com

                  


          

        

      

    

     

    
      	
            	4.2.	
              Payments
      detailed in section 2 shall be conditioned upon payment for Complete
      Visits and shall be included in the first invoice sent by the Medical
      Center.

            


    

     

    
      	
            	4.3.	
              Payment
      shall be maid by BioCancell within 30 (thirty) days of receipt of the
      Medical Center’s invoice.

            


    

     

    
      
        	
              	4.4.	
                All
      Payments shall he performed in the last day of the calendar year during
      which the relevant payment date occurred. (Occurrence of the relevant
      payment date shall be at the termination and completion of the stage and
      conditions of which entitles the Medical Center for payment according to
      this Appendix C).

              


      

    

     

    
      	
            	4.5.	
              Immediately
      upon receiving the payment as per the issued invoice the Medical Center
      will provide BioCancell with a receipt approving the
    payment.

            


    

     

    
      	5.	
              Currency of
      Payments

            


    

     

    All of
the payments subject of this Appendix C shall be performed by BioCancell to the
Medical Center in NIS (New Israel Shekel).

     

    
      	6.	
              General Observations and
      Clarifications

            


    

     

    For the
sake of good order it is hereby clarified that, unless otherwise agreed upon in
writing by BioCancell:

     

    
      	
            	6.1.	
              No
      payment would be performed for any activities performed by the Principal
      Investigator and/or by the Medical Center, prior to the commencement of
      the Trial. 

            


    

     

    
      	
            	6.2.	
              Without
      derogating from any right of BioCancell, in the event that no Completed
      CRF's are provided to BioCancell, regarding a Subject, in relation to
      which BioCancell has performed payments to the Medical Center, BioCancell
      shall be entitled to perform one of the following three, according to its
      absolute discretion:

            


    

     

    
      	
            	6.2.1.	
              Write-off
      the amount paid by BioCancell in relation to Subject(s) for which no
      Completed CRFs have been provided (hereinafter: “the Return
      Amount”) from the
      amount remaining due to the Medical Center by BioCancell according to this
      Agreement (hereinafter: “the Remaining
      Amount”).

            


    

     

    
      	
            	6.2.2.	
              Order
      the Medical Center, in writing, to pay BioCancell the Return Amount within
      a period no longer than 45 (forty-five) days from the End of the Trial,
      The Medical Center hereby undertakes that it shall pay the Return Amount,
      as specified above, and renounces any contentions and/or claims whatsoever
      in relation thereto.

            


    

     

    
      
        	
              	6.2.3.	
                In
      the event that the Return Amount shall exceed the remaining Amount,
      BioCancell shall be entitled to exercise its rights under the above
      sub-sections 6.3.1 arid 6.3.2 in concert, to the extent that BioCancell
      shall fully collect the Return Amount from the Medical
    Center.

              


      

    

     

    
      	
            	6.3.	
              No
      advance payments would be performed by BioCancell to the Medical
      Center.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

       

    

     

    
      
        
          
            	
                    

                  	
                    8
      Hartom St, Jerusalem Israel 97775

                    Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                    www.biocancell.com
      info@biocancell.com

                  


          

        

      

    

     

    Appendix
D

     

    Schedule 4 of the
Guidelines

     

    
      	 
	
              Title
      of the trial: “Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in
      Patients with Intermediate-Risk Superficial Bladder
  Cancer”

            
	 
	
              The
      protocol name and number: BC-07-01

            
	 
	
              Name
      of the investigational product: DTA-H19/PEI

            
	 
	
              Name
      of the Principal Investigator:

            	
              Department:

              Urology

            
	 	 
	
              Name
      of the medical institution:

            
	 
	
              The
      Sponsor’s name and address: BioCancell Therapeutics Ltd., Beck Science
      Center, 8 Hartom St., Jerusalem 97775,
Israel

            


    

     

    
      	1.	
              Sponsor
      undertaking

            


    

     

    
      	 	
              
                The
      Sponsor undertakes to act in accordance with the local and international
      law for clinical trials, and in particular with regard to the following
      issues:

              

            


    

     

    
      	
            	1.1.1.	
              Responsibility
      for the safety and good order of the investigational
    product;

            


    

     

    
      	
            	1.1.2.	
              Supply
      of information regarding the trial;

            


    

     

    
      	
            	1.1.3.	
              Notice
      to the Ministry of Health regarding the performance of a multi-centre
      trial in Israel;

            


    

     

    
      	
            	1.1.4.	
              Monitoring
      the trial process;

            


    

     

    
      	
            	1.1.5.	
              Safety
      reports;

            


    

     

    
      	
            	1.1.6.	
              Accountability
      in respect of the investigation
product;

            


    

     

    
      	
            	1.1.7.	
              Retention
      of documents.

            


    

     

    
      	2.	
              The
      Sponsor undertakes that if it shall decide to publish the results of the
      clinical trial in scientific literature, it shall publish them in full and
      without taking matters out of their
context.

            


    

     

    
      	3.	
              Insurance:

            


    

     

    
      	
            	3.1.	
              The
      Sponsor undertakes to insure its legal liability pursuant to the laws of
      the State of Israel against claims that may be filed by subjects in the
      clinical trial and/or third party claims – all in connection with the
      clinical trial, whether in the period of conducting the clinical trial or
      thereafter. The insurance shall be extended to include the legal liability
      of the medical institution and/or the clinical trial personnel and/or the
      Principal Investigator (hereinafter referred to as “the parties conducting the
      trial”)
      deriving from their Involvement in the conduct of the clinical trial,
      subject to an exception of an act committed negligently or an intentional
      deviation from the clinical trial
protocol.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          
            	
                    

                  	
                    8
      Hartom St, Jerusalem Israel 97775

                    Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                    www.biocancell.com
      info@biocancell.com

                  


          

        

      

    

     

    
      	
            	3.2.	
              The
      Sponsor shall be given notice of any claim or any potential claim
      immediately after such comes to the knowledge of the medical institution
      or the Principal Investigator.

            


    

     

    
      	
            	3.3.	
              The
      Principal Investigator, the medical institution and its employees shall
      give the Sponsor, upon its written request, reasonable support in any
      event of a claim that may be filed against it as
  aforesaid.

            


    

     

    
      	4.	
              The
      Sponsor undertakes to supply the medical institution with the
      investigational product throughout the period of the clinical trail until
      the conclusion thereof, free of charge. Furthermore, the Sponsor
      undertakes to pay all additional costs deriving from the conduct of the
      clinical trail, provided that such costs do not derive from the regular
      medical treatment of the sickness.

            


    

     

    
      	5.	
              If
      after the termination of the clinical trial it is ascertained and
      recommended by the Principal Investigator that the welfare of the patient
      participating in the clinical trial necessitates continuation of his
      treatment with the investigational product and there is no other
      appropriate alternative medical treatment, the Sponsor undertakes to also
      continue supplying the investigational product, without charge, after the
      termination of the clinical trial for a period of three years, except in
      one of the following cases:

            


    

     

    
      	
            	5.1.	
              The
      investigational product was approved for marketing in the State of Israel
      after its registration for its requested scope and it can be obtained from
      the sick fund with which the patient is
insured.

            


    

     

    
      	
            	5.2.	
              The
      development of the product was discontinued or the results of the clinical
      trials were unsuccessful.

            


    

     

    
      	
            	5.3	
              The
      administration of the investigational product for the said protracted
      period is likely to harm the patient’s health, since there is insufficient
      information regarding the safety of the product administered over the long
      term.

            


    

     

    
      	
            	5.4.	
              Where
      the investigational product is not a medical preparation, such as:
      cosmetic products / food / food additive / herbal
  remedy.

            


    

     

    The
decision as to the continuation of administering the investigational product is
given to the medical institution’s Helsinki Committee (“the Helsinki
Committee”), that
is entitled to re-examine its determination from time to time. The Principal
Investigator and the Sponsor have a right of appeal against such decision to the
Ministry of Health’s director-general or such person as empowered by him such
regard.

     

    
      	6.	
              The
      continued administration of the investigational product after termination
      of the clinical trial is subject to the following terms and
      conditions:

            


    

     

    
      	
            	6.1.	
              The
      continued treatment shall be given within the context of an orderly
      monitoring protocol that shall be written by the Principal Investigator
      and approved by the Sponsor and the Helsinki
  Committee.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          
            	
                    

                  	
                    8
      Hartom St, Jerusalem Israel 97775

                    Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                    www.biocancell.com
      info@biocancell.com

                  


          

        

      

    

     

    
      	
            	6.2.	
              The
      Principal Investigator is responsible for continuing to routinely monitor
      the subject’s medical condition and to report to the Helsinki Committee
      any exceptional events that occur during the ongoing treatment, as is the
      norm in clinical trials.

            


    

     

    The
principal investigation shall report to the Helsinki Committee at least once a
year as to the progress of the subject’s treatment.

     

    The
medical institution in which the ongoing treatment shall be given shall attend
to appropriate insurance cover for the liability of the medical institution and
the Principal Investigator vis-a-vis the patient, in respect of the continuation
of administering the investigational product after the termination of the
clinical trial.

     

    
      	7.	
              This
      Appendix constitutes an integral part of the agreement between the company
      sponsoring the clinical trial and the medical
  institution.

            


    

     

    
      
        	
                BioCancell
      Therapeutics Ltd.

                 

                By: /s/Avi
      Barak 

                 

                Print
      Name: Avi Barak 

                 

                Title:
      CEO

              	
                Meir
      Medical Center

                 

                By:
      /s/ Victor
      Vishlitzky

                 

                Print
      Name: Victor Vishlitzky M.D.

                 

                Title:
      Deputy Director 

                Meir
      General Hospital

                Kfar Saba,
      Israel

              
	
                By:
      /s/ Patricia Ohana
      

                 

                Print
      Name: Patricia Ohana

                 

                Title:
      VP Clinical Development 

              	
                By:_____________________

                 

                Print
      Name:_______________

                 

                Title:____________________

              


      

    

     

    I the
undersigned, Dr. Ilan Leibovitch MD, hereby declare and confirm that I have read
and understood this Appendix D.

    
      	 	 	 	 
	/s/ Ilan
      Leibovitch 	 	 	 
	
              
      The Principal Investigator	 	 	
            


    

    
       

      Meir-final agreement

       

    

    
      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

    

     

    
      
        
          
            
              	
                      

                    	
                      8
      Hartom St, Jerusalem Israel 97775

                      Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                      www.biocancell.com
      info@biocancell.com

                    


            

          

        

      

    

     

    Appendix E

     

    The Trial Documents and Related
Activities

     

    The Trial
Documents shall include, inter alia, all the documents set forth in the
Guidelines, as well as the documents specified hereunder.

     

    Any and
all terms not specifically defined in this Appendix shall have the meaning
attributed to them in the Agreement.

     

    Prior to the initiation of the
Trial:

    

      
        	1.	
                The
      executed signature page of the Trial Protocol;
  and

              


      

    

     

    
      	2.	
              Investigator
      Brochure; and

            


    

     

    
      	3.	
              The
      current curriculum vitae of the Principal Investigator;
  and

            


    

     

    
      	4.	
              The
      list of all sub-investigators, all of which necessarily being listed on
      either the FDA form no. 1572, or on the Principal Investigator’s Statement
      Form; and

            


    

     

    
      	5.	
              The
      written approval of the Medical Center Helsinki Committee, indicating that
      it has reviewed and approved the Trial Protocol;
  and

            


    

     

    
      	6.	
              The
      written approval of the MOH with regards to the content of all publicity
      and advertisements, related to the Trial, which are to be performed prior
      to the commencement of the Trial;
and

            


    

     

    
      	7.	
              A
      list of all participants in the Helsinki Committee, convened in relation
      to the Trial (hereinafter: “the Helsinki
      Committee”);
      and 

            


    

     

    
      	
            	7.1.	
              Should
      the Principal Investigator be a member of the Helsinki Committee, the
      written Statement of the chairman of the Helsinki Committee confirming
      that the Principal Investigator did not participate in the voting,
      relating to the Trial, during the hearing of the said Helsinki Committee;
      and 

            


    

     

    
      	
            	7.2.	
              A
      financial disclosure form, confirming that the Principal Investigator
      holds no financial interests in
BioCancell.

            


    

     

    While conducting the
Trial:

     

    
      	1.	
              A
      review of all the Trial Documents and verification the accuracy and
      completeness thereof in relation to the source documents, on which the
      above documents were based; and

            


    

     

    
      	2.	
              Report
      to the Medical Center Helsinki Committee of any Severe Adverse Events, as
      such terms are defined in the Trial Protocol, to the Subject(s), in
      accordance with the Guidelines; and

            


    

     

    
      	3.	
              Report
      to the Medical Center Helsinki Committee of any deviation from the Trial
      Protocol; and

            


    

     

    
      	4.	
              Maintain
      adequate records of Subjects identification, clinical observations, as
      well as study drug receipt and dispensation (hereinafter: “the
      Records”),
      in accordance with any applicable laws, rules, regulations and guidelines,
      as amended from time to time. In any event, the Principal Investigator and
      BioCancell shall maintain the Records for a period of no less than 15
      (fifteen) years following the end of the
Trial.

            


    

    
       

      Meir-final agreement

       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          
            	
                    

                  	
                    8
      Hartom St, Jerusalem Israel 97775

                    Phone:
      +972-2-548-6555 Fax: +972-2-548-6550

                    www.biocancell.com
      info@biocancell.com

                  


          

        

      

    

     

    
      	5.	
              Compare
      the data in the CRF with the source documents relating to each subject
      participating in the Trial, and confirm the accuracy of the CRF;
      and

            


    

     

    
      	6.	
              Maintain
      a log, documenting the Product(s) provided to each subject during the
      Trial; and

            


    

     

    
      	7.	
              Report
      no later than 7 (seven) days before additional quantities of Product(s)
      are required to proceed with the
Trial.

            


    

     

    
      	8.	
              Complete
      all CRFs

            


    

     

    
      	9.	
              Re-validate
      the approval of the relevant Helsinki Committee to the Trial, within a
      reasonable time prior to its expiration
date.

            


    

     

    
      	10.	
              A
      written detailed periodic report on the progress of the Trial in the said
      period (section 17.3 of the
Agreement).

            


    

     

    At the end of the
Trial:

     

    
      	1.	
              All
      Completed CRFs;

            


    

     

    
      	2.	
              A
      summary report, which shall include, in a full and detailed manner, a
      declaration regarding the activities performed during the Trial and the
      results obtained therein (section 17.4 of the
  Agreement).

            


    

    
       

      Meir-final agreement